A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Clinical trial NCT00781911 · COMPLETED

Trial details

NCT number: NCT00781911
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma Neuroendocrine Tumors

Start date: 2009-02-01
Primary completion: 2011-07-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.